
A02 A novel orthotopic ovarian patient derived xenograft model platform to investigate novel therapies for BRCA deficient ovarian cancers. Erin George, University of Pennsylvania, Philadelphia, PA, United States.

A03 Analyses of a prostate cancer patient-derived xenografts series, a resource for translational research. Nora Navone, MD Anderson Cancer Center, Houston, TX, United States.

A04 Combined anti-MET/EGFR treatment results in complete tumor regression and prevents resistance onset in a MET-amplified gastroesophageal xenopatient cohort. Silvia Giordano, Fondazione Piemontese per la Ricerca sul Cancro-ONLUS - University of Torino, Candiolo, Torino, Italy.

A05 Developing patient derived xenograft (PDX) models for metastatic castration resistant prostate cancer (CRPC) during CYP17 inhibitor therapy. Fang Xie, Mayo Clinic, Rochester, MN, United States.


A07 Molecular characterization of patient-derived xenograft models of pediatric brain tumors. Sebastian Brabetz, German Cancer Research Center (DKFZ), Heidelberg, Germany.

A08 Neurosphere culture captures the clinical and molecular diversity of glioblastoma tumors. Ana deCarvalho, Henry Ford Hospital, Detroit, MI, United States.


A10 Plerixafor inhibits myeloid cell recruitment and improves the radioresponse in patient-derived cervix cancer xenograft models. Naz Chaudary, Ontario Cancer Institute and Campbell Family Institute for Cancer Research, Toronto, Ontario, Canada.

A11 Using a patient-derived orthotopic xenograft (PDOX) model to screen drugs targeting renal cell carcinoma (RCC) metastasis—A personalized therapeutic strategy. Li Li, Ochsner Clinic Foundation, New Orleans, LA, United States.

A12 Developing PDeX (patient derived explant) to determine the basis for response to AR-directed therapeutics. Ayesha Shafi, Thomas Jefferson University, Philadelphia, PA, United States.

A13 Development of a drug response assessment platform for biopsy-derived tumor models. David Kodack, Massachusetts General Hospital, Boston, MA, United States.
Poster Session A
February 12, 2016
12:30 p.m.–3:30 p.m.
Elite Hall A


A16 Establishment and characterization of CCGL007, a novel human chronic lymphocytic leukemia cell line. Ching-Chuan Kuo, National Health Research Institutes, Zhunan, Taiwan.


A18 High content 3D image analysis of patient-derived organoids. Erin Spiller, University of Southern California, Los Angeles, CA, United States.


A20 Personalized models to guide precision medicine. Chantal Pauli, Institute for Precision Medicine, WCM, New York, NY, United States.

A21 Accurate molecular fidelity of patient-derived xenograft (PDX) models to original human tumors and to The Cancer Genome Atlas (TCGA). Jennifer Jaskowiak, Champions Oncology, Hackensack, NJ, United States.

A22 Breast cancer patient-derived xenograft (PDX) models developed in “humanized” mice. Roberto Rosato, Houston Methodist Cancer Center, Houston, TX, United States.

A23, PR03 Characterizing the immune context of responses to immunotherapy in humanized patient derived xenograft models of CRC. Anna Capasso, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

A24 Early-stage pancreatic cancer patient derived xenograft (PDX) models established from endoscopic ultrasound (EUS) fine needle aspiration (FNA) biopsies. Kerrington Smith, Dartmouth Hitchcock Medical Center, Lebanon, NH, United States.


A27 Addiction to the NF-κB-triggered IGF2-ID1-IGF2 circuit for maintenance of the breast cancer stem-like cells. Noriko Gotoh, Cancer Research Institute, Kanazawa University, Kanazawa City, Japan.

A28 Challenging new epigenetic vulnerabilities in human metastatic melanoma PDXs. Luisa Lanfrancone, European Institute of Oncology, Milano, Italy.

A29 Evaluating the dynamics of epigenetic changes conferring targeted cancer drugs resistance in tumor xenograft propagation model. REN-IN YOU, Tzu Chi University, Hualien, Taiwan.

A30 Modeling an immunotherapy of NK mechanism on a NSCLC patient derived xenograft. Henry Li, Crown Bioscience, Santa Clara, CA, United States.


A33 The implication of patient derived tumor cell (PDTC) tested/screened with novel microtube array membrane (MTAM)-based hollow fiber assay (HFA). Chien-Chung Chen, Taipei Medical University, Taipei, Taiwan.

A34 A comprehensive panel of patient-derived orthotopic xenograft mouse models of malignant brain tumors. Lin Qi, Texas Children’s Cancer Center; Departments of Pediatrics, Baylor College of Medicine, Houston, TX, United States.


A37 Dual wavelength near-infrared fluorescence imaging of VEGF-A and IGF-1R in ovarian cancer patient-derived xenografts. Steven De Jong, University Medical Center Groningen, Groningen, Netherlands.


A39 Patient-derived xenografts to test emerging therapies for triple negative breast cancer. Kurt Evans, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Poster Session A  
February 12, 2016  
12:30 p.m.–3:30 p.m.  
*Elite Hall A*

**A40 The ImmunoGraft™: A humanized mouse model for translational assessment of immunotherapy in solid tumors.** Angela Davies, Champions Oncology, Hackensack, NJ, United States.

**A41 Use of patient-derived tumor xenografts (PDX) for discovery and development of an anti-Notch2/3 monoclonal antibody targeting cancer stem cells.** Marcus Fischer, OncoMed Pharmaceuticals, Redwood City, CA, United States.

**A42 Using a PDX tumor bank to screen for cancer stem cell therapies.** James Evans, OncoMed Pharmaceuticals, Redwood City, CA, United States.